Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men

What Was Tested

Researchers studied Glucagon in the context of insulin resistance, prediabetes & type 2 diabetes in this randomized controlled trial publication.

This study's aim was to define the effects of GLP-1 on water and sodium excretion in both healthy and obese men.

Why It Was Studied

Glucagon-like peptide-1-(7-36)-amide (GLP-1) is involved in satiety control and glucose homeostasis.

Who Took Part

According to the abstract, 16 men were involved.

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The men were allocated by chance, so the Glucagon group and the comparison group should start out alike.

Blinding on both sides kept the men and researchers unaware of who received Glucagon.

Some men received a placebo instead of Glucagon, giving a reference point.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

What Was Measured

The subject headings attached to it are Blood Glucose, Drinking, Glomerular Filtration Rate, Glucagon, Glucagon-Like Peptide 1, Insulin and Insulin Resistance.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 16 men in people with insulin resistance, prediabetes & type 2 diabetes.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2004 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Glucagon compound page, Insulin resistance, prediabetes & type 2 diabetes research.